180 Life Sciences’ Bold Gamble: A $425 Million ETH Pivot

After a dramatic 99% stock decline, Nasdaq-listed biotech firm 180 Life Sciences is making a high-stakes move. The company is launching an ambitious cryptocurrency strategy, aiming to raise $425 million to invest primarily in Ethereum (ETH). This bold pivot follows a trend of struggling companies turning to crypto in search of a turnaround. The decision has sparked considerable debate among investors, highlighting the increasing intersection of traditional finance and the volatile cryptocurrency market. This risky bet underscores the desperate measures some companies are taking to survive in challenging economic times. Is this a lifeline or a gamble too far? We delve deeper into the details, examining the potential risks and rewards of this unprecedented move.